LOS ANGELES — Dynamo Delay has announced that its topical anesthetic treatment has once again surpassed the industry’s production standards of the United States Pharmacopeia (USP).
The male genital desensitizing spray reportedly topped the U.S.’s newest microbial requirements for Cosmetic/OTC and Pharmaceutical products, ensuring consumer protection against the Burkholderia cepacia group of bacteria.
Consistent with the company's safety-first philosophy, Dan Holman, Dynamo’s senior account executive, remarked, "We never compromise on quality and always ensure we exceed all standards. USP is the preeminent authority in the U.S. on pharmaceutical products, and we follow all of their requirements scrupulously."
Dynamo Delay is touted as the "ultimate on-the-spot treatment for men who suffer from premature ejaculation." Made in California using solar power, "its formulation is 35 percent stronger than its closest retail contenders and the spray adheres to the most stringent quality and safety standards set by the FDA," offered a Dynamo rep.
Vice President Conde Aumman added, "Dynamo Delay is now a well-established player in this space,” noting that the company has officially incorporated the new manufactured goods standards into all of parent company Screaming O’s testing and release protocols.
For additional details about Dynamo Delay, click here.
